Table 3.
Advanced lipoprotein at baseline before randomization and after 24 weeksa stratified by treatment arm: (A) triple therapy, (B) TNFi; (C) comparison of advanced lipoprotein measurements across treatment arms
| A. Triple therapy, n = 61 | ||||
|---|---|---|---|---|
| Lipids | Baseline | 24 weeks | Δ | p-valueb |
| ApoB, mg/dL | 98.5 (16.4) | 94.5 (18.3) | -5.4 (15.1) | 0.02 |
| LDL particle size, nm | 21.1 (0.5) | 21.2 (0.4) | 0.1 (0.3) | 0.004 |
| LDL-P, nmol/L | 1383.8 (317.7) | 1308.5 (335.8) | -75.3 (270.8) | 0.048 |
| ApoA1, mg/dL | 137.3 (25.9) | 133.4 (24.4) | -3.9 (20.8) | 0.19 |
| HDL-P, umol/L | 22.2 (3.9) | 20.9 (4.0) | -1.2 (3.1) | 0.01 |
| apoB/apoA1 | 0.74 (0.21) | 0.72 (0.19) | -0.02 (-0.06) | 0.31 |
| B. TNFi + MTX, n = 61 | ||||
|---|---|---|---|---|
| Lipids | Baseline | 24 weeks | Δ | p-value |
| ApoB, mg/dL | 95.0 (15.3) | 95.6 (16.7) | 0.5 (12.1) | 0.73 |
| LDL particle size, nm | 21.1 (0.4) | 21.2 (0.4) | 0 (0.3) | 0.60 |
| LDL-P, nmol/L | 1296.1 (269.0) | 1336.0 (344.7) | 39.9 (197.6) | 0.12 |
| ApoA1, mg/dL | 128.4 (21.4) | 134.7 (22.1) | 6.3 (19.0) | 0.01 |
| HDL-P, umol/L | 20.1 (3.5) | 21.3 (3.7) | 1.2 (3.1) | 0.004 |
| apoB/ApoA1 | 0.75 (0.16) | 0.72 (0.18) | -0.03 (0.06) | 0.02 |
| C. Comparison of changes in advanced lipoprotein measurements between treatment arms (TNFi vs. triple therapy). | |||
|---|---|---|---|
| Lipids (mg/dL) | Beta | 95% CI | p-value |
| ApoB, mg/dL | 4.5 | -0.3, 9.4 | 0.07 |
| LDL particle size, nm | -0.08 | -0.19, 004 | 0.20 |
| LDL-P, nmol/L | 102.6 | 14.2, 190.9 | 0.02 |
| ApoA1, mg/dL | 6.7 | -0.5, 13.8 | 0.07 |
| HDL-P, umol/L | 1.7 | 0.6, 2.9 | 0.004 |
| apoB/ApoA1 | -0.01 | -0.05, 0.04 | 0.76 |
aAll lipids in mg/dL and reported as mean (SD); no subjects on statins
ball p-values from paired t-test
Abbreviations apoA1 = apolipoprotein A; apoB = apolipoprotein B; LDL-P = LDL particle number; HDL-P = HDL particle number; LDL = low density lipoprotein